Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Juvantia
Turku, Finlandjuvantia.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Juvantia Pharma was a Finnish clinical-stage biotechnology company specializing in the development of small molecule therapeutics for central nervous system (CNS) disorders. The company's primary focus was on the alpha-2C adrenergic receptor, leading to the development of its flagship candidate, fipamezole, for the treatment of levodopa-induced dyskinesia in Parkinson's disease. Founded as a spin-off from the University of Turku, Juvantia successfully advanced fipamezole through Phase 2b clinical trials. In 2009, the company was acquired by Santhera Pharmaceuticals, which sought to expand its portfolio in movement disorders.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Biovail
Beyond the preview
Go deeper on Juvantia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Juvantia.